220 related articles for article (PubMed ID: 28319603)
1. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
Patel D; Park KT
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
3. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
5. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
6. A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
Ha CY; Kornbluth A
Inflamm Bowel Dis; 2016 Oct; 22(10):2513-26. PubMed ID: 27564646
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
Fiorino G; Fazio M; Danese S
Expert Rev Clin Immunol; 2016; 12(4):361-3. PubMed ID: 26752540
[No Abstract] [Full Text] [Related]
9. Inflammatory diseases: Integrating biosimilars into clinical practice.
Feldman SR
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
[TBL] [Abstract][Full Text] [Related]
10. Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence.
Strand V; Evans C; Gibofsky A
Am J Manag Care; 2022 Nov; 28(12 Suppl):S217-S226. PubMed ID: 36493395
[TBL] [Abstract][Full Text] [Related]
11. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in inflammatory bowel disease.
Moore GT
Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
[No Abstract] [Full Text] [Related]
13. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
14. The rise of biosimilars: How they got here and where they are going.
Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
[TBL] [Abstract][Full Text] [Related]
15. Friction in the Path to Use of Biosimilar Drugs.
Frank RG
N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182
[No Abstract] [Full Text] [Related]
16. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
17. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
18. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
Pentek M; Zrubka Z; Gulacsi L
Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
[TBL] [Abstract][Full Text] [Related]
19. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
Felice C; Pugliese D; Armuzzi A
Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
[No Abstract] [Full Text] [Related]
20. Biosimilars for immune-mediated inflammatory diseases: a managed care perspective.
Evans C; Gibofsky A; Strand V
Am J Manag Care; 2022 Nov; 28(12 Suppl):S234-S239. PubMed ID: 36493397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
